Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com - Stifel initiated coverage on Catalyst Biosciences (NASDAQ:CBIO) with a Buy rating and a $28.00 price target on Tuesday. For a comprehensive analysis of CBIO’s Fair Value and detailed financial metrics, check out InvestingPro, where subscribers can access exclusive insights and valuation tools.
The research firm cited the company’s CR-001 drug candidate as an attractive opportunity for exposure to the emerging PD-(L)1xVEGF bispecific class, which could potentially disrupt a market worth over $50 billion currently dominated by PD-(L)1-targeting monoclonal antibodies. Unlock dozens of additional ProTips and expert analysis about CBIO’s market position with InvestingPro.
Stifel highlighted that CR-001 is engineered to replicate the pharmacology of ivonescimab while maintaining its status as a new molecular entity, allowing Catalyst to leverage upcoming proof-of-concept Phase 1 data expected by year-end 2026 to accelerate development timelines.
The firm projects peak sales exceeding $7.5 billion across lung, gastrointestinal, and gynecological cancers, suggesting significant value creation potential even without biological or mechanistic differentiation from existing therapies.
Stifel also noted that Catalyst’s earlier-stage ADCs (antibody-drug conjugates) equipped with TOPO1 inhibitors provide additional opportunities for long-term competitive differentiation through combination therapies with CR-001.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.